A5093971265- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Nutrition and Health in Aging
- Liver Diseases and Immunity
- Hepatitis C virus research
- Pancreatitis Pathology and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cardiovascular Disease and Adiposity
- Hepatocellular Carcinoma Treatment and Prognosis
- Gallbladder and Bile Duct Disorders
- Clinical Nutrition and Gastroenterology
- Microscopic Colitis
- Dysphagia Assessment and Management
- Inflammatory Bowel Disease
- Inflammatory Biomarkers in Disease Prognosis
- Hepatitis B Virus Studies
- Diet, Metabolism, and Disease
University of Campania "Luigi Vanvitelli"
2024-2025
Alpha-Glutathione-S-transferase (alphaGST) is a liver enzyme whose serum levels increase with the worsening of fibrosis in alcoholic and viral chronic hepatitis. Its usefulness Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) remains unexplored. From January 2016 to December 2017, 200 patients MASLD 30 controls were enrolled. AlphaGST measured. Variables related advanced (AF) selected via Principal Component Analysis (PCA), best cut-off (BCO) was estimated using ROC analysis....
Background: Hepatobiliary liver cancers (HBLCs) represent the sixth most common neoplasm in world. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) constitute main HBLC types, with alarming epidemiological projections. Methods: In recent decades, alterations gut microbiota, mutual implications on gut–liver axis gut–biliary permeability status, have been massively investigated proposed as pathogenetic deus ex machina. Results: HCC setting, elevated intestinal levels of Escherichia...
BACKGROUND For compensated advanced chronic liver disease (cACLD) patients, the first decompensation represents a dramatically worsening prognostic event. Based on event (DE), transition to decompensated (dACLD) can occur through two modalities referred as acute (AD) and non-AD (NAD), respectively. Clinically Significant Portal Hypertension (CSPH) is considered strongest predictor of in these patients. However, due its invasiveness costs, CSPH almost never evaluated clinical practice....
Biological antioxidant potential (BAP) and Reactive Oxygen Metabolites (dROMs) are two tests complementarily assessing systemic oxidative statuses (SOSs) that never applied in chronic liver disorders (CLDs). We enrolled 41 ursodeoxycholic acid (UDCA)-naïve Primary Biliary Cholangitis (PBC) patients [age: 58.61 ± 11.26 years; females (F): 39], 40 with metabolic-dysfunction-associated steatotic livers (age: 54.30 11.21; F: 20), 52 HBV 52.40 8.22; 34), 50 56.44 7.79, 29), 10 controls 52.50...
Background: Unlike other chronic liver disorders, in primary biliary cholangitis (PBC), systemic oxidative stress (SOS) worsens along with disease progression status (DPS), influencing muscle metabolism, quantity (MQ), and itch pathways. Synergistically, cholestasis contributes to reduced vitamin D absorption, a negative impact on MM SOS. Despite this evidence, the prevalence of sarcopenia PBC, SOS-MQ relationship comparing PBC CLDs, has never been investigated. Moreover, between MQ-SOS,...